Tests proton radiation at higher doses for inoperable soft tissue sarcoma
Tests higher-dose proton radiotherapy in adults with inoperable soft tissue sarcoma.
Plain-language title generated from the registry record
Registry title: Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Key facts
- Where
- Bergen and Oslo, NorwaySee the 2 sites
- Phase
- Phase 2
Where in Norway
- Haukeland University HospitalBergen, NorwayNot yet recruiting
- Oslo University HospitalOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT07173972
- Record updated
- 28 January 2026
- Original description
The purpose of the study is to study if dose escalated proton radiotherapy can improve local controll for patients with inoperable soft tissue sarcomas. The standard treatment is photon-based radiation. By using proton radiotherapy instead, the hypothesis is that the dose can be increased to enhance treatment effectiveness without increasing side effects.Read full original descriptionShow less
PROSARC-2. Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. A Single-arm, Multicenter, Phase II Clinical Trial.
The purpose of the study is to study if dose escalated proton radiotherapy can improve local controll for patients with inoperable soft tissue sarcomas. The standard treatment is photon-based radiation. By using proton radiotherapy instead, the hypothesis is that the dose can be increased to enhance treatment effectiveness without increasing side effects.
The planned radiation dose is 56 Gy in 16 fractions (treatments) over 4 weeks (4 fractions per week), with a maximum dose escalation centrally in the tumor up to 80 Gy (5 Gy per fraction).
At the same time, the study will investigate biomarkers that can predict treatment response, including changes in the tumor's genetic material (DNA), measurements of various molecules in the bloodstream, and the tumor's appearance on MRI scans.
The primary endpoint is local control after 2 years, meaning that the treated tumor has not grown during this period. Secondary endpoints include overall survival, progression-free survival, radiological response rates, side effects, and quality of life.
The study will be conducted in Norway, with a planned inclusion of 40 patients.
Inclusion: ≥ 18 years of age at the time of informed consent; Histological diagnosis of soft tissue sarcoma including gastrointestinal stromal tumor (GIST); Measurable disease according to RECIST v1.1; Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; For patients with metastatic disease a life-expectancy greater than 2 years should be expected; Before patient registration, written informed consent must be given according to national and local regulations; Ability to fill in patient questionnaires and comply with study procedures, including travelling to Bergen or Oslo for Proton Beam radiotherapy.
Exclusion: Patients with a prior or concurrent malignant disease whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible. Patients with a history of breast cancer, requiring continued hormonal treatment (e.g. anti-estrogen or an aromatase inhibitor) may be included. Patients with a history of prostate cancer, requiring continued support with luteinizing hormone releasing hormone (LHRH) agonists, with or without androgens, may be included; Previous radiotherapy to the tumor site; Administration of systemic cancer therapy (i.e. chemotherapy, targeted therapy or immune therapy) within 14 days prior to the first fraction of radiotherapy; Patients with pacemakers and/or implanted defibrillators; Patients not able to give an informed consent or comply with study regulations as deemed by study investigator.